TABLE 8.

Results of pairwise meta-analyses for mortality.

Comparative medication	Reference medication	Number of studies	Pairwise meta-analyses
			Number of control	Number of patients	MD/OR/RR	95% CI	I2	P
Ligustrazine	Placebo	3	321	322	1.67	[1.02, 2.67]	95	< 0.05
Heparin	Placebo	9	2703	1145	0.9	[0.74, 1.09]	1	0.42
tPA	Placebo	4	814	804	1.04	[0.75, 1.43]	NA	0.83
Stent retrievers	Placebo	5	653	634	0.81	[0.58, 1.12]	29	0.19
Alpha 1	Placebo	6	467	595	1.05	[0.7, 1.59]	0	0.8
Cerebrolysin	Placebo	7	971	808	0.82	[0.55, 1.22]	0	0.81
Ginkgo biloba	Placebo	12	213	228	1.21	[0.29, 5.09]	43	1.8
Stem cell-based therapy	Placebo	9	218	217	0.6	[0.35, 1.03]	4	0.4
Tirofiban	Placebo	6	218	223	0.53	[0.13, 2.07]	63	0.1
Albumin	Placebo	4	1928	1938	1.1	[0.9, 1.34]	0	0.51
Intra-A	Placebo	5	171	224	0.83	[0.48, 1.39]	0	0.46
Edaravone plus rt-PA	Placebo	4	474	472	0.43	[0.13, 1.42]	0	0.87
Statins	Placebo	18	3034	3021	0.85	[0.77, 0.93]	0	0.003
DZSM	Placebo	5	341	340	0.54	[0.31, 0.95]	85.9	0.23
TNK	Placebo	4	658	676	1.03	[0.69, 1.52]	0	0.9
Cilostazol	Placebo	6	1728	1731	0.80	[0.42, 1.53]	0	0.52

CI, confidence interval; MD, mean difference; OR, risk ratio; I², heterogeneity; Intra-A, intra-arterial fibrinolysis; rt-PA, alteplase; TNK, tenecteplase.